Bio-Rad LaboratoriesBIO

NYSE · USA · Segment 6 of 8 in the Medicine, pharma & life science value chain: Diagnostics

Clinical diagnostics laboratories buy one part of the range, blood typing among the uses; life science researchers buy the other, for work such as droplet digital PCR.

Diagnostics: Tests, imaging and assays that support clinical decision-making.

Key metrics

Market cap

$9.7B

Price

$381.76

Today

+0.5%

Return YTD

+25.4%

Return 1Y

+33.3%

P/E

43.5

P/S

3.7

P/B

1.3

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

DiagnosticsLife science toolsResearch equipment

In the value chain

Products & services

Clinical diagnostics
Life science research equipment
Digital PCR

Competitors

Thermo Fisher
Danaher
Qiagen

Risks

Cyclical research demand
Value tied to Sartorius stake

Supply chain

Supplies →

LabcorpLH

Full supply chain for BIO →

Same segment: Diagnostics

Abbott LaboratoriesABT NateraNTRA IDEXX LaboratoriesIDXX LabcorpLH Quest DiagnosticsDGX HologicHOLX

Compare BIO

BIO vs ABT BIO vs NTRA BIO vs IDXX BIO vs LH BIO vs DGX BIO vs HOLX

See where Bio-Rad Laboratories sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →